Furthermore, we have demonstrated that CAF secretion of NRG-1 actively circumvents the inhibitory effect of erlotinib and promotes tumour growth providing an ‘escape’ mechanism to EGFR-targeted therapy. This evidence concerns the gene EGFR and neoplasm.